MedTrace Logo

Ascorbic Acid to Prevent Postreperfusion Syndrome in Liver Transplantation

NCT05754242 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-03-03

No results posted yet for this study

Summary

The goal of this clinical trial is to test the efficacy of intravenous ascorbic acid in preventing the postreperfusion syndrome in liver transplantation. The main questions it aims to answer are:

* Can intravenous ascorbic acid prevent postreperfusion syndrome in liver transplantation ?
* Can ascorbic acid decrease the incidence of liver graft dysfunction after liver transplantation?
* Can ascorbic acid decreased the incidence of postoperative complications after liver transplantation ?

Participants will receive 1.5 g of intravenous ascorbic acid diluted in 100 ml of saline or 100 ml of saline alone, during the anhepatic phase of liver transplantation before reperfusion of the new graft.

Researchers will compared the incidence of postreperfusion syndrome in both groups.

Conditions

  • Liver Transplantation
  • Postreperfusion Syndrome
  • Ascorbic Acid

Interventions

DRUG

Ascorbic acid

1.5 gr of ascorbic acid

DRUG

0.9% Saline solution

100 ml of 0.9% saline solution

Sponsors & Collaborators

  • Hospital Universitario Ramon y Cajal

    lead OTHER

Principal Investigators

  • Luis Gajate, MD PhD · Hospital Universitario Ramón y Cajal

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
67 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-17
Primary Completion
2023-06-30
Completion
2023-07-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05754242 on ClinicalTrials.gov